InVivo Therapeutics Announces Adjournment of Annual Meeting
June 14 2019 - 8:00AM
Business Wire
- Scheduled to Reconvene on July 2, 2019 -
- Company urgently encourages stockholders to
vote -
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today
announced that its 2019 Annual Meeting of Stockholders, scheduled
for June 11, 2019, was convened and adjourned without any business
being conducted due to the fact that quorum was not achieved. The
Annual Meeting will be reconvened July 2, 2019 to allow more
opportunity for stockholders to vote on all proposals described in
the Company’s definitive proxy statement filed with the Securities
and Exchange Commission (SEC) on April 25, 2019.
It has come to the Company’s attention that certain stockholders
may have been unable to vote their shares through their broker or
financial institutions, particularly if such shares are held
through European institutions. The Company encourages any
stockholder that has not received communications from their brokers
or banks or is uncertain if its shares have been voted to contact
the Company’s proxy specialists at the number listed below in order
to help facilitate the voting of shares.
In order for the Company to achieve quorum, the Company’s board
of directors and management respectfully requests all such holders
as of the record date to please vote their proxies as soon as
possible, but no later than July 1, 2019 at 11:59 pm ET. The
Company also reminds holders to inquire with their voting
institutions about any additional clearing time that may be
required to forward voting instructions to the Company in advance
of the July 1, 2019 deadline. The record date for the Annual
Meeting remains April 22, 2019. Company stockholders as of the
record date can vote, even if they have subsequently sold their
shares. Stockholders who have previously submitted their proxy or
otherwise voted and who do not want to change their vote need not
take any action.
For questions relating to the voting of shares or to request
additional or misplaced proxy voting materials, the Company’s proxy
specialists may be reached at 1-888-742-1305 between the hours of
9:00 a.m. and 6:00 p.m. Eastern time Monday through Friday.
Stockholders who hold their shares through a bank or broker can
vote through Broadridge using one of the methods below:
Vote By Internet Vote By Telephone
Vote By Mail
http://www.proxyvote.com
Use the Internet to transmit your voting
instructions until 11:59 p.m. Eastern Time on Monday, July 1, 2019.
Have your proxy card in hand when you access the website. You will
be prompted to enter your control number to create and submit an
electronic ballot.
1-800-454-8683(VOTE)
Use any touch-tone telephone to transmit
your voting instructions until 11:59 p.m. Eastern Time on Monday,
July 1, 2019. Have your proxy card in hand when you call. You will
be prompted to enter your control number; and then follow the
directions given.
Mark, sign and date your proxy card and
return it in the enclosed postage-paid envelope.
Registered stockholders (stockholders who do not hold
their shares through a bank or broker) are urged to complete, sign,
date and mail their proxy card at their earliest convenience. Any
registered stockholder who would like to vote by telephone may call
866-894-0536. Registered stockholders may also vote online at
www.cstproxyvote.com.
A copy of the company’s proxy statement as previously filed with
the SEC is available at no charge on the SEC website at
www.sec.gov. In addition, copies of the proxy statement and other
documents may be obtained free of charge by accessing the Company’s
website at www.invivotherapeutics.com or by contacting the
Company’s Corporate Secretary at 617-710-1233 or by mail to
Corporate Secretary, InVivo Therapeutics, One Kendall Square,
Building 1400 West, Floor 4, Cambridge, MA 02139.
YOUR PARTICIPATION IS IMPORTANT - PLEASE
VOTE TODAY!
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a
research and clinical-stage biomaterials and biotechnology company
with a focus on treatment of spinal cord injuries. The company was
founded in 2005 with proprietary technology co-invented by Robert
Langer, Sc.D., Professor at Massachusetts Institute of Technology,
and Joseph P. Vacanti, M.D., who then was at Boston Children’s
Hospital and who now is affiliated with Massachusetts General
Hospital. The publicly traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190614005031/en/
IR CONTACT:Bret Shapiro, Managing PartnerCORE IRPhone:
(516) 222-2560brets@coreir.com
MEDIA CONTACT:Jules AbrahamCORE IRPhone: (917)
885-7378julesa@coreir.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Sep 2023 to Sep 2024